



GLAND PHARMA LIMITED

October 17, 2023

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Re-appointment of Independent Director of the Company

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; We would like to inform you that, based on the recommendation of Nomination and Remuneration Committee, the Board of Directors in its Meeting held on October 17, 2023 had reappointed Mr. Satyanarayana Murthy Chavali (DIN:00142138) as an Independent Director for a term of five years with effect from 20th November, 2023, subject to the approval of the Shareholders of the Company through a postal ballot and e-voting.

We also confirm that the Director reappointed is not debarred from holding the office of Director pursuant to any order of the SEBI or any such other Authority.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** enclosed herewith.

The Board Meeting commenced at 11:00 Hrs IST and concluded at 15:15 Hrs (IST).

This is for your information and records.

**Yours truly,
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer**

**Annexure A**

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Details of Mr. Satyanarayana Murthy Chavali

Sl. No	Particulars	Remarks
1	Reason for change & Date of Change	The tenure of Mr. Satyanaryana Murthy Chavali as an Independent Director will be completed by 19 th November, 2023. Hence, the Board had reappointed Mr. Satyanarayana Murthy Chavali as an Independent Director for another term of five years with effect from 20 th November, 2023, subject to the approval of shareholders.
2	Brief profile	<p>Mr. Satyanarayan Murthy Chavali worked at various leadership roles, a substantial portion in globally focused Pharma / R&D (drug discovery/ clinical development) business. He has rich experience in Venture financing and Investment Banking.</p> <p>He is a director on the Board of Directors of Vijaya Diagnostic Centre Limited. He is also the Founder & CEO of Satya_{Rx} Pharma Innovations Private Limited, a drug discovery biotech Company.</p> <p>Mr. C.S.N. Murthy was associated with Aurigene Discovery Technologies Limited (currently Aurigene Oncology Limited) as the Chief Executive Officer. He was associated with ICICI Ventures and had his own boutique firm of Investment Banking during 1990-2000.</p> <p>Mr. Satyanarayana Murthy Chavali holds a bachelor's degree in technology from Indian Institute of Technology, Madras (Chennai) and a post graduate diploma in management from Indian Institute of Management, Bangalore.</p>
3	Disclosure of relationships between director	Not related to any other director or KMP of the Company